Review
Sep 2026
Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.
Her2 TKIs may be the preferred initial option over ADCs in advanced HER2 mutated NSCLC, given their higher response rates, particularly in YVMA insertions, a more favorable safety profile, and preserved ADC efficacy following TKI exposure.
Molly S. C. Li, Yu Yang Soon, Pui-Yin Au-Yeung et al.
· Journal of Thoracic Oncology · 0 citations